Consumers and health plans that paid for covered generic drugs between 2009 and 2019 have until November 9, 2026 to claim from the $275 million Sandoz and Fougera generic drug price-fixing settlement. It is the only one of Sandoz’s three generic drug settlements open to consumer claims, and it is filed through the combined end-payer claim.
What Is This About?
The claim deadline for the $275 million Sandoz settlement is less than six weeks away. Sandoz Inc. and its subsidiary Fougera Pharmaceuticals settled the claims of the end-payer class in In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 16-MD-2724, in the U.S. District Court for the Eastern District of Pennsylvania, and the court granted final approval on September 26, 2025. The settlement is now being paid out through a combined claim with two other end-payer settlements, Sun/Taro and Apotex/Heritage, and that claim must be filed online or postmarked by November 9, 2026.There is no separate Sandoz claim form. Filing the end-payer claim is how consumers and health plans claim the Sandoz money; the full filing guide, covered drugs and proof requirements are on the generic drug end-payer settlements page.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Sandoz Has Three Generic Drug Settlements
The Sandoz name appears on three different generic drug settlements, and only one of them takes consumer claims now:| Sandoz settlement | Who it is for | Can consumers claim now? |
|---|---|---|
| $275 million end-payer settlement (Sandoz and Fougera) | Consumers and health plans that paid for covered drugs | Yes, by November 9, 2026, through the end-payer claim |
| Direct purchaser settlement (2024) | Pharmacies, wholesalers and distributors that bought directly from Sandoz | No, not a consumer settlement |
| $400 million settlement in principle with the states (August 2026) | State attorneys general | No, not final and not part of any open consumer program |
The state attorneys general do run an open consumer program, but it pays out about $96.5 million from five other companies, not Sandoz, and has its own claim with a March 8, 2027 deadline. It is covered on the state AG generic drug consumer settlement page.
Who Can Claim the Sandoz Money?
The end-payer classes cover consumers who paid all or part of the cost of covered generic prescription drugs in the United States between May 1, 2009 and December 31, 2019, and the health insurers, employer plans and union benefit funds that reimbursed those costs. The covered drugs include hundreds of common generics, and the claim requires records of the purchases, such as pharmacy records, receipts or insurer statements.Background on Sandoz and the Generic Drug Cases
Sandoz, which Novartis spun off as a separate company in 2023, is one of the generic manufacturers accused of conspiring to fix prices, allocate customers and rig bids for generic drugs from 2009 to 2019. Fougera, its subsidiary, makes generic topical medications such as creams and ointments. Sandoz resolved federal criminal charges with the U.S. Department of Justice in 2020 and settled the direct purchaser class claims in 2024 before reaching the $275 million end-payer settlement, which contains no admission of wrongdoing.On February 2, 2026, a coalition of states sued Novartis and Sandoz entities over 31 additional generic drugs, and in August 2026 a coalition of 43 states and territories announced a $400 million settlement in principle with Sandoz. The state claims are allegations, and that settlement is not final. Many other defendants in the generic drug litigation have not settled, and the cases against them continue.
Questions
How do I claim from the Sandoz $275 million settlement?
File the combined generic drug end-payer claim at GenericDrugsEndPayerSettlement.com or by mail by November 9, 2026. There is no separate Sandoz claim form; one end-payer claim covers the Sandoz/Fougera, Sun/Taro and Apotex/Heritage settlements.
What is Fougera?
Fougera Pharmaceuticals is a Sandoz subsidiary that makes generic topical medications such as creams and ointments. It is a party to the same $275 million end-payer settlement as Sandoz.
Can I claim from the $400 million Sandoz settlement with the states?
Not yet. The states announced the $400 million settlement in principle in August 2026, and it is not final. It is not part of the state attorneys general consumer program now open at AGGenericDrugs.com, which pays out about $96.5 million from five other companies with a March 8, 2027 deadline.
Is the Sandoz settlement a sign Sandoz admitted wrongdoing?
The $275 million end-payer settlement contains no admission of wrongdoing by Sandoz. Separately, Sandoz resolved federal criminal charges with the U.S. Department of Justice in 2020.
Sources
• Official generic drugs end-payer settlement website• Sandoz Group AG announcements of the end-payer and direct purchaser class settlements
• In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 16-MD-2724 (E.D. Pa.), final approval of the Sandoz/Fougera end-payer settlement (September 26, 2025)
• State attorneys general announcements of the February 2026 Novartis/Sandoz complaint and the August 2026 Sandoz settlement in principle
